stoxline Quote Chart Rank Option Currency Glossary
  
Psyence Biomedical Ltd. (PBM)
1.36  -0.02 (-1.45%)    02-07 19:17
Open: 1.38
High: 1.44
Volume: 78,095
  
Pre. Close: 1.38
Low: 1.36
Market Cap: 5(M)
Technical analysis
2025-02-07 4:46:37 PM
Short term     
Mid term     
Targets 6-month :  2.17 1-year :  2.65
Resists First :  1.86 Second :  2.26
Pivot price 1.58
Supports First :  1.21 Second :  1
MAs MA(5) :  1.43 MA(20) :  1.63
MA(100) :  4.48 MA(250) :  33.38
MACD MACD :  -0.3 Signal :  -0.3
%K %D K(14,3) :  22.6 D(3) :  24.6
RSI RSI(14): 37.4
52-week High :  323.25 Low :  1.21
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PBM ] has closed above bottom band by 14.3%. Bollinger Bands are 86.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 93 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.44 - 1.45 1.45 - 1.46
Low: 1.34 - 1.35 1.35 - 1.36
Close: 1.35 - 1.36 1.36 - 1.38
Company Description

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Headline News

Fri, 27 Dec 2024
Psyence Biomed Announces Closing of $2.0 Million Private Placement - GlobeNewswire

Tue, 24 Dec 2024
Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position - Yahoo Finance

Mon, 23 Dec 2024
Psyence Biomedical Achieves Full Nasdaq Compliance, Advances Clinical Trial Plans with $5.6M War Chest - StockTitan

Tue, 17 Dec 2024
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial - GlobeNewswire

Tue, 10 Dec 2024
Psyence Biomed Secures Landmark Global Psilocybin Supply Deal for Palliative Care Drug Development - StockTitan

Tue, 10 Dec 2024
Psyence Biomed Executes Binding Agreements with Optimi Health Corp. - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 4 (M)
Shares Float 2 (M)
Held by Insiders 2.7 (%)
Held by Institutions 9.4 (%)
Shares Short 76 (K)
Shares Short P.Month 10 (K)
Stock Financials
EPS -76.92
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.82
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -126.4 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.71
Qtrly Earnings Growth 0 %
Operating Cash Flow -3 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio -0.02
PEG Ratio 0
Price to Book value -1.67
Price to Sales 0
Price to Cash Flow -1.81
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android